Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial
Luis Paz‐Ares(Instituto de Biomedicina de Sevilla), Filippo de Marinis(Carlo Forlanini Hospital), Mircea Dediu(Institutul Oncologic Bucuresti), Michael Thomas(Heidelberg University), Jean-Louis Pujol(Centre Hospitalier Universitaire de Montpellier), Paolo Bidoli(Azienda Ospedaliera San Gerardo), Olivier Molinier(Centre Hospitalier du Mans), Tarini Prasad Sahoo(Jawaharlal Nehru Cancer Hospital and Research Centre), Eckart Laack(Universität Hamburg), Martin Reck(LungenClinic Grosshansdorf), J. Corral(Instituto de Biomedicina de Sevilla), Symantha Melemed(Eli Lilly (United States)), William J. John(Eli Lilly (United States)), Nadia Chouaki, Annamaria H. Zimmermann(Eli Lilly (United States)), Carla Visseren‐Grul(Eli Lilly (Netherlands)), Cesare Gridelli(Azienda Ospedaliera S.Giuseppe Moscati)
Cited by 613Open Access
Abstract
Related Papers
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer et al.|JNCI Journal of the National Cancer Institute|2000|15.7k
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Martin M. Oken, Richard H. Creech, Douglass C. Tormey et al.|American Journal of Clinical Oncology|1982|11.6k
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
Giorgio V. Scagliotti, Purvish Parikh, Joachim von Pawel et al.|Journal of Clinical Oncology|2008|3.2k
Analysis of Binary Data
Cox, David Roxbee|Unknown|2008|2.7k